Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pomaglumetad methionil in first-episode psychosis and clinical high risk for psychosis
ACTRN12626001320347Phase 2Not yet recruiting
- Sponsor
- Orygen
- Start
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pomaglumetad methionil in psychosis and Clinical high risk for psychosis (CHR), sponsored by Orygen. Primary endpoints: Safety of pomaglumetad methionil, Acceptability and tolerability of pomaglumetad methionil and 1 more. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
pomaglumetad methionil
03
Conditions
psychosisClinical high risk for psychosis (CHR)
Beyond the preview
Go deeper on ACTRN12626001320347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12626001320347.